Sold, Not Measured

Every figure describes services a practice listed on its own website when it was read, not clinical conduct — see Definitions and Methodology. Data collected July 18 – September 2, 2026 (about 55% in July and 45% in August). Analysis computed September 2, 2026. Data: JSON, CSV under each table.

Summary

Longevity medicine's premise is measurement first: know the biomarkers, then intervene. Whelth Research's national census verified 3,549 U.S. practices offering longevity medicine (see the 2026 report). For this brief we split each practice's published menu into interventions and diagnostics and asked how often the first is sold without the second.

1,100 practices — 31% of the category — sell at least one intervention while offering no diagnostic service of any kind, not even blood testing. Among the 2,149 practices selling hormone therapy, 86.9% list none of the seven measurements most associated with longevity medicine. Only 13.4% of all practices list any of those seven. Med spas account for 55.4% of the practices that sell with no diagnostic listed; dedicated longevity clinics are the least likely to (14.7%) — but even there, three in four hormone sellers list no frontier measurement.

Definitions

A service counts only when the practice's own website evidences it (captured verbatim at review time). Categories used in this brief:

Medical weight loss is classed as an intervention because, in this market, it is predominantly GLP-1 prescribing. Functional-medicine testing qualifies a practice for the census but is not counted as a diagnostic here, since it is a discipline rather than a specific test.

By intervention

Of the practices selling each intervention, the share that offers no blood testing, and the share that offers no diagnostic service at all.

Three in ten practices selling testosterone therapy (30.2%) list no blood-testing service — the one measurement TRT prescribing is built on. Two in five peptide sellers (41.5%) and 44.5% of medical-weight-loss providers list none either. Ozone therapy — which FDA regulation 21 CFR 801.415 describes as "a toxic gas with no known useful medical application" — is sold by 9.1% of the category, and 38.9% of those practices list no diagnostic service.

By practice type

The pattern is the med-spa-ization of longevity medicine. 43% of med spas offering longevity services list them with no diagnostic service, and med spas are 55.4% of every practice in the country that does. Measured against blood testing alone, 55.4% of med spas selling longevity interventions list no blood-testing service on their menu, versus 42.1% of medical practices and 24.5% of dedicated longevity clinics; med spas are 52.6% of all such sellers. Dedicated longevity clinics list the most measurement — 27.1% list a frontier measurement, nearly four times the med-spa rate — yet 75.1% of their hormone sellers still list none of the seven.

By state

States with at least 40 verified practices, ranked by the share selling without any diagnostic service.

Maryland (45.7%), Kentucky (37.3%) and Oregon (37.0%) have the highest share of longevity practices listing interventions with no diagnostic; Kansas (10.9%), Massachusetts (16.4%) and Nevada (19.2%) the lowest. Indiana has the thinnest diagnostic layer of any state in the table — 5.2% of its practices list a frontier measurement. Pennsylvania, the most underserved large state by count, has the deepest: 28%.

Aesthetics vs. diagnostics

A verified longevity practice is seven times more likely to list Botox (38%) than a DEXA scan (5.3%), and more of them list dermal fillers (32.2%) than a biomarker panel (15.1%). 21% sell NAD+ infusions and 31% sell peptide therapy — the compounded category the FDA moved to restrict in 2023–24.

Methodology

Population. The 3,549 practices are the qualifying set of Whelth Research's 2026 national census of longevity medicine as of 2 September 2026: every U.S. city of 25,000+ reviewed; a practice counts when its own website evidences at least one hard diagnostic service and services in at least two longevity categories, or when its entire model is longevity/preventive medicine. The inclusion gate, discovery funnel and limitations are published there and are not repeated here.

Classification. Each practice's evidenced services were mapped to the intervention, diagnostic, frontier and blood-testing sets defined above. A practice "sells without testing" when it offers at least one intervention and no diagnostic. Per-intervention rows are shares of the practices selling that intervention. State rows include states with at least 40 verified practices; each practice is counted once, at its primary location. Practice types follow the census taxonomy (dedicated longevity clinic, medical-practice hybrid, med-spa hybrid, concierge practice).

Limitations. The analysis sees what a practice publishes. A practice that orders labs through an outside laboratory without listing testing on its site is counted as offering no diagnostic; the figures therefore describe published menus, not clinical conduct, and are reported only as category shares. Nothing here characterizes any individual practice. Practice websites were read between 18 July and 2 September 2026 and the statistics computed on 2 September 2026; a menu can have changed since.

About Whelth

Whelth is a research platform and national directory for aesthetic, longevity and dental care, with structured profiles built from public records and each practice's own published materials. Whelth Research publishes original data reports from that directory. More at whelth.com/research.